Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAP-targeted iCDC in End-stage Dilated Cardiomyopathy
NCT06902896Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of FAP CAR-T cell therapy in dilated cardiomyopathy (DCM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Apr 2025; status: recruiting.
02
Drugs
FAP CAR-T cell therapy
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT06902896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902896.